Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Michelson, A. D.
Right arrow Articles by Furman, M. I.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Michelson, A. D.
Right arrow Articles by Furman, M. I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Resistance to antiplatelet drugs

Alan D. Michelson*, A. Lawrence Frelinger and Mark I. Furman

Center for Platelet Function Studies, Division of Cardiovascular Medicine, Departments of Pediatrics and Medicine, University of Massachusetts Medical School, Room S5-846, 55 Lake Avenue North, Worcester, MA 01655, USA

* Corresponding author. Tel: +1 508 856 0056; fax: +1 508 856 4282. E-mail address: michelson{at}platelets.org.

Antiplatelet drugs are beneficial in the treatment of coronary artery disease, ischemic stroke, and peripheral arterial disease. Platelet function tests have been studied in these cardiovascular diseases as a means to predict clinical outcomes and monitor antiplatelet drugs. There is a well-documented variability between patients (and normal volunteers) with regard to laboratory test responses to antiplatelet drugs. Evidence from small clinical studies suggest that decreased response, or ‘resistance’, to antiplatelet drugs is associated with subsequent major adverse clinical events. However, it remains unknown whether altering therapy based on platelet function tests is beneficial to patients.

Key Words: Platelets • Drug resistance • Aspirin • Clopidogrel • Thienopyridines • GPIIb–IIIa antagonists


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CirculationHome page
J. S. Li, E. Yow, K. Y. Berezny, P. M. Bokesch, M. Takahashi, T. P. Graham Jr, S. P. Sanders, D. Sidi, D. Bonnet, P. Ewert, et al.
Response to Letter Regarding Article, "Dosing of Clopidogrel for Platelet Inhibition in Infants and Young Children: Primary Results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) Trial"
Circulation, August 12, 2008; 118(7): e121 - e121.
[Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. D. Michelson
P2Y12 Antagonism: Promises and Challenges
Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): s33 - s38.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.